Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber...
Vaccine
Dyadic to Present at BioProcess International
JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
Poolbeg Pharma PLC Announces Interim Results for the Six Months to 30 June 2023
Significant progress made and well positioned for future growthLONDON, UK / ACCESSWIRE / September 13, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF),...
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate...
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild or moderate COVID-19 patients were...
IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
Encouraging interim data support the potential of IO102-IO103 in combination with pembrolizumab as first-line treatment in non-small cell lung cancerNEW...
Defence’s Broad and Versatile Accum(R) Technology Platform Focus on Cancer Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"...
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
Clinical data show robust immune responses across multiple circulating variants, including EG.5, FL.1.5.1, and BA.2.86Updated vaccine to be available in...
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
Evaxion is the first organization to validate an AI model that outcompetes state-of-the-art vaccine developmentEvaxion's AI model predicts vaccine efficacy...
Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
CAMBRIDGE, MA / ACCESSWIRE / September 8, 2023 / Moderna, Inc. (Nasdaq:MRNA) has been notified that TRC Capital Investment Corporation...
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Table 1 Table 1 Chart 1 Chart 1 Chart 2 Chart 2 Table 2 Table 2All study objectives were met,...
Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023
• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza from Janssen Pharmaceuticals, Inc. leadership...
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim...
Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference
CAMBRIDGE, MA / ACCESSWIRE / September 6, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in a fireside chat...
Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs
Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the...
Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or...
Inovalon Recognized as #1 Ranked Cloud-Based Data Platform Provider for Healthcare by Black Book Research
Leader in Data-Driven Healthcare Earns Top Ranking for Third Consecutive YearBOWIE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Inovalon, a...
IMUNON to Participate in the H.C. Wainwright Global Investment Conference
LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will...
Defence’s Innovative Therapeutics Featured on Viewpoint with Dennis Quaid
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"...
Walgreens Boots Alliance Announces Leadership Transition
Rosalind Brewer Steps Down as CEO and Member of the Board Ginger Graham, Current Lead Independent Director, Appointed Interim CEO...